Methods to treat cerebral ischemic injury and other neuronal diseases
CA 2261130 A1 · Owner: Whalley, Eric T. · Inventors: Relton, Jane K.; Whalley, Eric T.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates generally to the use of antagonists which selectively affect the bradykinin 2 receptor (B2) and/or agonists which selectively affect the B1 receptor, to treat cerebral ischemic injury whether , due to stroke or other causes and in particular to striatal ischemic injury and cortical ischemic injury. The present invention also relates to using B2 antagonists and/or B1 agonists to treat Parkinson's disease and Huntington's disease. The B2 antagonist and/or B1 agonist chosen can be used alone or together as the therapeutic agent or in combination with other therapeutic agents.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 15, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 15, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 15, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.